IngredientsStearoyl vanillylamide (abbreviated SVA or C18-VA) is a long-chain N-acyl vanillylamide belonging to the broader capsaicinoid chemical family. Stearoyl vanillylamide is a nonpungent capsaicin (CAP) analog — intravenous injection of C18-VA enhances adrenaline secretion significantly and as effectively as CAP in rats.
The molecular formula of stearoyl vanillylamide is C26H45NO3, with a molar mass of 419.6404 and a melting point of 94.5–95 °C.
Structurally, stearoyl vanillylamide shares the characteristic vanillyl head group (a 4-hydroxy-3-methoxybenzyl moiety) of capsaicin, but differs from capsaicin in having a saturated, straight-chain C18 (stearic acid–derived) acyl chain rather than capsaicin's branched, unsaturated C9 chain. Capsaicinoids and their close analogs are comprised of a relatively polar vanillyl head group, a long hydrophobic chain, and an amide or ester linkage; all three components have been identified as critical for the associated biological and pharmacological activities. The different capsaicinoid compounds have slight structural variations in the hydrocarbon tail, changing their ability to bind to nerve receptors; capsaicinoids are very similar in structure, varying only by the length of a long hydrocarbon portion and by the presence or absence of a carbon-to-carbon double bond in that hydrocarbon portion.
Stearoyl vanillylamide is a naturally occurring capsaicin analog found in red pepper species, and the CAS number is 58493-50-8. In its commercially supplied form it appears as a white to off-white powder with a reported assay purity of 98%.
The question of whether stearoyl vanillylamide is a bona fide natural product or primarily a synthetic analog is not fully resolved. Analysis shows that although some of these synthetic analogs eventually may prove to be true natural products, conclusive evidence based on isolation and structure elucidation is still absent after decades of attempted isolation from several potential natural sources. Some commercial suppliers describe it as "naturally occurring" in red pepper species, citing Capsicum oleoresin as a botanical source; others list Piper longum L. (long pepper) as the botanical origin on technical data sheets. Analysis shows that although some of these synthetic analogs eventually may prove to be true natural products, conclusive evidence based on isolation and structure elucidation is still absent after decades of attempted isolation from several potential natural sources. The broader capsaicinoid literature is informative here: while a closely related compound, N-vanillylnonanamide (NVA), was later discovered to be a natural product from capsicum oleoresin, it is commonly manufactured synthetically. The parallel situation likely applies to stearoyl vanillylamide — it may occur in trace quantities in Capsicum oleoresin fractions, but is commercially produced through synthesis.
To understand stearoyl vanillylamide, it is essential to understand its relationship to the capsaicinoid chemical family found in the genus Capsicum.
Peppers are native to Central and South America and Mexico, with their use as spices dating back more than 6,000 years. It was Columbus who introduced chilis to Spain in 1493, and in the following years these spices spread all over Europe, and later to India, Asia, and Africa.
Plants of the genus Capsicum are rich in a class of compounds known as capsaicinoids, with capsaicin being the most important. The "chemistry" of capsaicin dates back to 1816 when C.F. Buchholz extracted it in impure form, and it was obtained in nearly pure form by J.C. Tresh in 1876. Its burning and even painful sensations were first reported by R. Buchheim and E. Högyes in 1872 and 1877, respectively. The structure was finally elucidated by D.J. Bennett and G.W. Kirby in 1968.
There are six natural capsaicinoids. Although vanillylamide of n-nonanoic acid (nonivamide) is produced synthetically for most applications, it does occur naturally in Capsicum species. The most commonly occurring capsaicinoids are capsaicin (69%), dihydrocapsaicin (22%), nordihydrocapsaicin (7%), homocapsaicin (1%), and homodihydrocapsaicin (1%); capsaicin and dihydrocapsaicin are the most pungent.
Stearoyl vanillylamide belongs to a distinct subgroup of long-chain saturated vanillylamides that lie outside the classically enumerated capsaicinoids. The applications of capsaicin as a clinically viable drug are limited by its unpleasant side effects, such as gastric irritation, stomach cramps, and burning sensation; this has led to extensive research focused on the identification and rational design of second-generation capsaicin analogs, which possess greater bioactivity than capsaicin. The development of stearoyl vanillylamide sits within this broader framework of capsaicin analog research.
Capsaicinoids include seven homologous branched-chain alkyl vanillylamides (capsaicin, dihydrocapsaicin, homocapsaicin I, homocapsaicin II, nordihydrocapsaicin, homodihydrocapsaicin I, homodihydrocapsaicin II) and three straight-chain analogs: octanoyl vanillylamide, nonoyl vanillylamide (nonivamide), and decoyl vanillylamide. Stearoyl vanillylamide extends this structural series by incorporating an octadecanoyl (stearic acid) chain — the longest saturated acyl chain documented in this class.
Stearoyl vanillylamide itself has no documented independent history of traditional use. As a specific chemical entity — isolated or identified only in the modern era — it was not used as a distinct ingredient by any historical culture or traditional medicine system. Any traditional context for SVA derives entirely from the historical and ethnobotanical use of Capsicum peppers and their crude preparations, which contain the parent capsaicinoid family.
Peppers are native to Central and South America and Mexico, with their use as spices dating back more than 6,000 years. Indigenous peoples of the Americas employed Capsicum species in food preparation, ritual, and medicine millennia before European contact. A history of the use of Capsicum spp. and the predominant active ingredient, capsaicin — the parent compound of a group of vanillyl fatty acid amides — has been presented in peer-reviewed literature.
The crude, dark oleoresin extract of capsicum contains over 100 distinct volatile compounds and therefore may function in many ways dissimilar to capsaicin; the oleoresin continues to be marketed in products with a high degree of variability in efficacy. Within this oleoresin, trace amounts of longer-chain vanillylamides including potentially stearoyl vanillylamide may be present, but were not recognized or deliberately used in historical preparations.
In summary: the traditional use record for SVA is inherited from, not identical to, the traditions of Capsicum use. SVA as an individual compound is a product of twentieth- and twenty-first-century analytical chemistry and pharmacological research.
Unlike botanical extracts that contain numerous constituents, stearoyl vanillylamide is itself the active molecule. Its pharmacological activity arises from its capacity to engage the transient receptor potential vanilloid type 1 (TRPV1) channel and secondarily to activate adrenergic signaling pathways.
The analgesic activity of capsaicin is mediated by transient receptor potential subfamily vanilloid member 1 receptor (TRPV1), which belongs to the transient receptor potential superfamily of cation-channel receptors. The transient receptor potential vanilloid receptor family is comprised of six members (TRPV1–6); capsaicin functions as a classic agonist of the TRPV1 receptor.
Together with capsaicin, stearoyl vanillylamide is known to be one of the agents (aside from endogenous ligands, inflammatory mediators, and non-selective stimuli) that target and activate the TRPV1 (Transient Receptor Potential Vanilloid) which is located in the plasma membrane and is responsible for encoding integral membrane proteins which work as ion channels.
When TRPV1 is specifically activated on sensory fibers and non-neuronal cells, it results in the influx of calcium and sodium, which is necessary for membrane depolarization.
One of the most pharmacologically significant features of stearoyl vanillylamide relative to capsaicin is its lack of pungency. Unlike capsaicin, stearoyl vanillylamide is non-pungent, meaning it does not impart the "spicy" or irritative effects of capsaicin, which makes it easier to use in powder-form supplements. The mechanistic basis for this distinction was directly confirmed in animal research: substance P concentration in cerebrospinal fluid, which is involved in pain transmission and is the first direct measure of pungency, was not affected by C18-VA administration.
The structural basis for this non-pungency is the elongation of the acyl chain. The classical pungent capsaicinoids have C9–C11 branched or unsaturated chains; capsaicin analogs with longer saturated chains progressively lose pungency while retaining TRPV1 receptor affinity. N-acyl-vanillamide (NAVAM) analogues of capsaicin were developed several years ago as potential non-pungent analgesic compounds; N-oleoyl-vanillamide (olvanil) and N-arachidonoyl-vanillamide (arvanil), in particular, were described in several publications and patents to behave as potent anti-hyperalgesic compounds in experimental models of chronic and inflammatory pain.
The transient receptor potential cation channel V1 (TRPV1) activation by stearoyl vanillylamide stimulates the release of catecholamines — for example adrenaline and noradrenaline — in the adrenal medulla. Generally, like other capsaicin analogs, this compound acts by enhancing the release of epinephrine and norepinephrine.
The downstream consequence of catecholamine release is activation of brown adipose tissue. Noradrenaline is a major regulator of brown fat activation, through β3 adrenoreceptor activation. UCP1 expression is induced by sympathetic nervous system (SNS) signaling, which is activated by cold exposure and intake of specific food ingredients; noradrenaline released from sympathetic nerve endings binds to β3-adrenergic receptors and activates intracellular adenylate cyclase, increasing intracellular cyclic AMP (cAMP) levels, which activates protein kinase A (PKA), upregulating Ucp1 expression.
Increasing metabolism and thermogenesis in brown adipose tissue (BAT) can help in overcoming obesity; TRPV1 activation upregulates thermogenic proteins in BAT to counter diet-induced obesity.
The broader context from TRPV1 research confirms this cascade: TRPV1 activation in cultured adipocytic cell lines has been shown to induce browning phenotype in white adipocytes; TRPV1 activation prevented obesity by activating central and peripheral mechanisms which regulate metabolism and thermogenesis.
Beyond direct thermogenesis, stearoyl vanillylamide appears to promote lipid mobilization. Stearoyl vanillylamide elevated lipolysis and oxidation of free fatty acids in rats, leading to elevated exercise capacity. This effect was confirmed biochemically: adrenaline was significantly greater in C18-VA-treated mice than in controls at 2 hours post-dose; in a separate study, free fatty acids in serum were elevated in treated mice at 2 hours post-dose (P < 0.01), while serum glucose concentration was not affected.
In a study in which capsaicin and 37 structurally related vanillylamide and ester analogs were synthesized and evaluated for cytotoxic activity and tumor cell/non-tumor cell selectivity in vitro, seven analogs with superior potency and selectivity compared to capsaicin were identified; notably, vanillylamides with a C16–C18 chain exhibited IC50 values five-fold lower than capsaicin (15–84 µM), with selectivity indices up to 35. This finding is strictly preliminary and in vitro.
Key study (animal, 1998): The most directly relevant published research on stearoyl vanillylamide is a peer-reviewed animal study, published in the Journal of Nutrition (1998), examining swimming capacity in mice. Intravenous injection of C18-VA, a nonpungent capsaicin analog, enhances adrenaline secretion significantly and as effectively as CAP in rats; because swimming capacity was enhanced by CAP in mice due to CAP-induced adrenal catecholamine secretion, the investigators examined the effects of oral administration of C18-VA on swimming capacity using an adjustable-current water pool; male Std ddY 6-week-old mice were fed a commercial diet, and one group was orally administered C18-VA via a stomach tube.
Treated mice were able to swim longer before exhaustion than control mice (62.9 ± 5.6 vs. 49.6 ± 7.0 min, P < 0.05); the swimming capacity of two groups administered C18-VA (0.02 and 0.033 mmol/kg) was significantly greater than that of those administered vehicle alone (P < 0.05).
These results suggest that C18-VA increased swimming capacity of mice via adrenaline release, independent of pungency; in addition, the study suggests the usefulness of its application to humans.
Evidence strength: This is a single preclinical (animal, in vivo) study. Stearoyl vanillylamide is still under-researched, with only one preliminary study demonstrating performance benefits. There are no published human clinical trials specifically evaluating stearoyl vanillylamide for exercise capacity.
Indirect evidence from nonpungent capsaicin analog class (human clinical trial): While no published human clinical trial has specifically tested stearoyl vanillylamide for metabolic or weight-related outcomes, there is relevant human clinical evidence for the broader class of nonpungent capsaicin analogs (specifically the capsinoids capsiate and dihydrocapsiate).
Capsinoids — nonpungent capsaicin analogs — are known to activate brown adipose tissue (BAT) thermogenesis and whole-body energy expenditure (EE) in small rodents; BAT activity can be assessed by [18F]fluorodeoxyglucose–positron emission tomography (FDG-PET) in humans; the study aimed to examine acute effects of capsinoid ingestion on EE and analyze its relation to BAT activity in humans.
Eighteen healthy men aged 20–32 years underwent FDG-PET after 2 hours of cold exposure (19°C) while wearing light clothing; whole-body EE and skin temperature, after oral ingestion of capsinoids (9 mg), were measured for 2 hours under warm conditions (27°C) in a single-blind, randomized, placebo-controlled, crossover design; when exposed to cold, 10 subjects showed marked FDG uptake into adipose tissue of the supraclavicular and paraspinal regions (BAT-positive group), whereas the remaining 8 subjects (BAT-negative group) showed no detectable uptake. Capsinoid ingestion increases EE through the activation of BAT in humans.
A single oral ingestion of capsinoids increases energy expenditure in human individuals with metabolically active BAT, but not those without it, indicating that capsinoids activate BAT and thereby increase energy expenditure; this finding gave a rational explanation for discrepant results of the effects of capsinoids in previous studies.
This evidence — from capsinoids structurally related to but distinct from stearoyl vanillylamide — supports the plausibility of SVA's proposed mechanism but cannot be extrapolated directly as clinical evidence for SVA itself.
The relevant animal studies of SVA's action have been carried out only on mouse subjects and have not been carried out in humans.
Evidence strength: For SVA specifically — preclinical only. The BAT/energy-expenditure mechanism has human-level support for related capsinoids (capsiate, dihydrocapsiate), not for SVA itself.
Although not fully confirmed, some studies have shown that stearoyl vanillylamide may effectively reduce inflammation by activating TRPV1 and releasing adrenergic hormones. When TRPV1 is activated, it can be considered as a therapeutic agent for inflammation. These claims are largely mechanistic extrapolations from capsaicin research and from general TRPV1 biology.
The PMC-indexed review of TRPV1 and adipose thermogenesis notes that TRPV1 activation prevented obesity by activating central and peripheral mechanisms which regulate metabolism and thermogenesis. However, the specific anti-inflammatory action of SVA has not been evaluated in controlled human or animal studies and the claim remains at the level of hypothesis and in vitro inference.
Evidence strength: In vitro / mechanistic only; no clinical anti-inflammatory studies for SVA exist in the published peer-reviewed literature.
A 2025 study published in the peer-reviewed journal Molecules (PMC) evaluated a series of capsaicin-related vanillylamide analogs for in vitro cytotoxicity. Vanillylamides with a C16–C18 chain exhibited IC50 values five-fold lower than capsaicin (15–84 µM), with selectivity indices up to 35. Most compounds exhibited no toxicity and caused only minimal growth inhibition in normal fibroblasts, even at 100 µM; 7 out of 37 compounds, with IC50 values well below 10 µM, demonstrated tumor cell selectivity over non-tumor cells and were more active than capsaicin. These findings relate to the structural series that includes SVA, though the specific compound tested may differ from SVA by functional group modifications.
A majority of natural capsaicinoids and synthetic capsaicin analogs have been studied for their pain-relieving activity; only a few of these capsaicin analogs have been investigated for their anticancer activity in cell culture and animal models.
Evidence strength: In vitro cell culture only. No animal or human data exist for anti-cancer applications of SVA specifically. These findings are not applicable to any clinical claim.
Stearoyl vanillylamide is commercially available primarily as a white to off-white powder for incorporation into dietary supplement formulations. It is also used, to a lesser extent, in topical/cosmetic preparations. Standard bulk purity in commercial supply is reported at 98%.
Dosages from published animal studies: The swimming capacity of two groups administered C18-VA (0.02 and 0.033 mmol/kg) was significantly greater than that of those administered vehicle alone (P < 0.05). Given the molecular weight of approximately 419.64 g/mol, these molar doses (0.02–0.033 mmol/kg) correspond to approximately 8.4–13.8 mg/kg body weight in the mouse model.
Dosages from human supplement use: Some supplement product labels have referenced doses of approximately 20 mg per serving. However, no pharmacokinetic or dose-finding studies in humans have been published for SVA specifically. As of now, there is no established common dosage for stearoyl vanillylamide due to the need for further research; dosage recommendations will likely be refined as more studies are conducted to understand its effects and optimal usage.
Human clinical comparator dosage: For context, the related class of nonpungent capsaicin analogs (capsinoids) has been studied in humans at a dose of 9 mg orally in a single-blind, randomized, placebo-controlled, crossover design. These data pertain to capsinoids (capsiate/dihydrocapsiate), not to SVA, and cannot be applied directly.
There are no studies of stearoyl vanillylamide on human bodies; most sport supplement products that claim stearoyl vanillylamide can enhance performance are extrapolating effects seen in mice and could possibly be promising.
A primary reason SVA has attracted interest over capsaicin itself is its non-pungency. Though some animal research and experiments state its usefulness in humans, there are still not enough data and human testing is still ongoing; humans may tolerate SVA better because it has lesser pungency compared to capsaicin, which cannot be taken in large amounts due to its greater pungency.
The pungency profile of the parent compound capsaicin is well characterized: a problem with capsaicin is its high acute toxicity (LD50 mouse oral 47 mg), which makes it difficult to apply in preparations, and the chronic gastritis, kidney damage, and liver damage which occur with frequent use and overdose. While SVA's lack of pungency suggests a potentially more favorable GI tolerability profile, this has not been confirmed in formal human tolerability studies.
Because SVA stimulates the release of catecholamines (adrenaline and noradrenaline), cardiovascular effects represent a theoretically important safety consideration. Catecholamines elevate heart rate and blood pressure. Capsaicin has a variety of pharmacological actions on the cardiovascular and respiratory system, and on the nervous system; topical application of CAP to the skin evokes pain and may be followed by a period of desensitization. While TRPV1 agonism in peripheral tissues may produce different cardiovascular effects than central agonism, no dedicated cardiovascular safety assessment for SVA has been published.
Given that SVA's principal documented mechanism involves the release of epinephrine and norepinephrine, pharmacodynamic interactions with other stimulants (caffeine, synephrine, ephedrine, beta-adrenergic agonists) are plausible. SVA is typically formulated in multi-ingredient pre-workout or fat-loss supplements alongside other stimulants. No peer-reviewed interaction studies have been published for SVA specifically.
Research on the closely related capsinoids reveals an important source of inter-individual variability relevant to SVA: when exposed to cold, 10 out of 18 subjects showed marked FDG uptake into adipose tissue (BAT-positive group), whereas the remaining 8 subjects (BAT-negative group) showed no detectable uptake; capsinoids, acting at the intestinal level through TRPV1, can activate the already present BAT. This implies that the metabolic effects of TRPV1 agonists — including potentially SVA — may be highly dependent on the individual's existing BAT activity.
Stearoyl vanillylamide does not appear on any approved food additive or novel food lists reviewed by authoritative bodies such as the U.S. FDA (GRAS), EFSA, or the European Commission as a specifically evaluated ingredient. It is marketed as a dietary supplement ingredient in various jurisdictions. No official monograph from the European Pharmacopoeia, USP, WHO, ESCOP, or German Commission E specifically addresses SVA. The overall safety and regulatory status remains unestablished by any official body.
Understanding SVA's current research context requires situating it within the broader scientific investigation of non-pungent capsaicin analogs.
Accumulating evidence has suggested that prolonged administration of either capsaicin or capsinoids (non-pungent capsaicin analogues) for several weeks resulted in beneficial effects on fat oxidation, energy expenditure, insulin sensitivity, and body fat mass in both rodents and adult humans.
Capsaicin and its nonpungent analogs (capsinoids) are known to be food ingredients that increase energy expenditure and decrease body fat; the role of brown adipose tissue for the thermogenic effect of these compounds in humans has been reviewed.
These findings, robust for capsinoids such as capsiate, provide the biological plausibility for the parallel claims made about SVA; however, SVA is a structurally distinct molecule (saturated C18 vs. the ester-linked C9/C10 chains of capsinoids), and its pharmacokinetics, oral bioavailability, receptor binding kinetics, and downstream effects have not been separately validated in human subjects.
The research data obtained from mice housed at 21°C may not translate to humans, who live in thermoneutrality. This general limitation, articulated in the capsaicin/BAT literature, applies equally to SVA's preclinical data.
The following table summarizes the state of evidence for each primary area of proposed activity:
Health conditions that Stearoyl vanillylamide may help support.
Body systems that Stearoyl vanillylamide may help support.
Go back